The Financial Times has a spot for the Alzheimer’s drug too, focusing on the trial results released by US pharmaceutical group Eli Lilly. The company has submitted donanemab for approval by the US Food and Drug Administration and expects a decision this year, according to the paper. In other news, under a headline reading “Losing pace”, there is a report about China’s economy growing by “just 0.8%” – the business paper predicts this could “pile pressure on global growth”.